General Information
Drug ID
DR00347
Drug Name
Olmesartan medoxomil
Synonyms
Benevas; Benicar; Benicar (TN); Benicar, Olmetec,Olmesartan; Berlin-Chemie Brand of Olmesartan Medoxomil; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Olmesartan medoxomil (JAN/USAN); Olmetec; Olmetec (TN); Olvance; Sankyo Brand of Olmesartan Medoxomil
Drug Type
Small molecular drug
Indication High blood pressure [ICD11: BA00] Approved [1]
Therapeutic Class
Antihypertensive Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=130881"></iframe>
3D MOL 2D MOL
Formula
C29H30N6O6
Canonical SMILES
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O<br />CC5=C(OC(=O)O5)C)C(C)(C)O
InChI
InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
InChIKey
UQGKUQLKSCSZGY-UHFFFAOYSA-N
CAS Number
CAS 144689-63-4
Pharmaceutical Properties Molecular Weight 558.595 Topological Polar Surface Area 154
Heavy Atom Count 41 Rotatable Bond Count 11
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 10
PubChem CID
130881
PubChem SID
10242742 , 103770675 , 104253234 , 104373834 , 11364900 , 11367462 , 11370024 , 11372810 , 11374179 , 11378194 , 11484167 , 11488322 , 11491491 , 11492555 , 11495758 , 11528908 , 12014934 , 124637431 , 124757358 , 124891848 , 125164162 , 125311925 , 125341111 , 126624592 , 126655597 , 126655871 , 126669975 , 14935211 , 26612826 , 26681017 , 26748978 , 26748979 , 29309387 , 48185250 , 48334789 , 53789233 , 57343590 , 7300489 , 7848267 , 78528258 , 81040868 , 81092830 , 85209756 , 85787984 , 92124799 , 92308046 , 92308894 , 92713789 , 93302267 , 93815139
ChEBI ID
CHEBI:31932
TTD Drug ID
D07UBG
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [3]
OAT1 Transporter Info Organic anion transporter 1 Substrate [3]
OAT3 Transporter Info Organic anion transporter 3 Substrate [3]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [4]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP2 Transporter Info Km = 14.9 microM LLC-PK1 cells-MRP2 [3]
MRP4 Transporter Info Km = 26.2 microM LLC-PK1 cells-MRP4 [3]
OAT1 Transporter Info Km = 0.0683 microM Human embryonic kidney cells (HEK293)-OAT1 [3]
OAT3 Transporter Info Km = 0.12 microM Human embryonic kidney cells (HEK293)-OAT3 [3]
OATP1B1 Transporter Info Km = 12.8 microM Human embryonic kidney cells (HEK293)-OATP1B1 [3]
OATP1B1 Transporter Info Km = 42.6 microM Oocytes-OATP1B1 [4]
OATP1B3 Transporter Info Km = 44.2 microM Human embryonic kidney cells (HEK293)-OATP1B3 [3]
OATP1B3 Transporter Info Km = 71.8 microM Oocytes-OATP1B3 [4]
References
1 Olmesartan medoxomil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
3 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
4 OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
5 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.